Jack M. Neuzillet, Cailin Traynor, Grace Hullmann, Gabriel Tyritzis, John Shimizu¹∗
Esophageal cancer is the seventh leading cause of cancer death in males in USA, Interleukin (IL)-32 is a recently identified proinflammatory cytokine that is one of the IL-18 inducible genes, and plays an important role in autoimmune and inflammatory diseases. IL-32 is recently described in esophageal cancer pathway via induction of nuclear factor NF-κB activation. We investigated the expression of IL-32 by TNF-α in esophageal cancer. Human esophageal cancer cells were cultured in the presence or absence of TNF-α to analyze the expression of IL-32 by quantitative RT-PCR and enzyme-linked immunosorbent assay. Further, activation of Akt and JNK signaling pathways were investigated by Western blot. TNF-α induced enhanced IL-32 release in human esophageal cancer cells. These data suggest that activation of Akt and JNK pathways regulated TNF-α-induced IL-32 expression in human esophageal cancer. We concluded that TNF-α/IL-32 pathway may be a potential marker and may be therapeutic target for esophageal cancer.
Keywords: Esophageal cancer; IL-32; TNF-α; Akt and JNK pathways; NF-κB activation
Copyright © 2016 by The American Society for BioMedicine and BM-Publisher, Inc.
1. Dawsey SP, Tonui S, Parker RK, et al. Esophageal cancer in young people: a case series of 109 cases and review of the literature. PLoS One 2010; 5: e14080. [PubMed]
2. Parkin DM, Bray F, Ferlay J, Pisani P. (2005) Global cancer statistics. Ca-A Cancer Journal for Clinicians 2002; 55: 74–108. [PubMed]
3. Sumeruk R, Segal I, Te Winkel W, Van Der Merwe CF. Oesophageal cancer in three regions of South Africa. South African Medical Journal 1992; 81: 91–93. [PubMed]
4. Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and mortality in Europe. International Journal of Cancer 2008; 122: 1118–1129. [PubMed]
5. Semnani SH, Besharat S, Abdolahi N, et al. Esophageal cancer in northeastern Iran. Indian Journal of Gastroenterology 2005; 24: 224. [PubMed]
6. Siegel R, Ward E, Brawley O, Jemal. Cancer statistics, the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212–236. [PubMed]
7. Yousif NG, Al-Amran FG, Hadi N, Lee J, Adrienne J. Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine 2013;61(1):223-7. [PubMed]
8. Eda H, Shimada H, Beidler DR, Monahan JB. Proinflammatory cytokines, IL-1β and TNF-α, induce expression of interleukin-34 mRNA via JNK- and p44/42 MAPK-NF-κB pathway but not p38 pathway in osteoblasts. Rheumatol Int. 2011;31(11):1525-30. [PubMed]
9. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005; 22:131-142. [PubMed]
10. Kang YH, Park MY, Yoon DY, et al. Dysregulation of overexpressed IL32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-κB and Bcl-2. Cancer Lett 2012; 318: 226-233. [PubMed]
11. Seo EH, Kang J, Kim KH, et al. Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol 2008; 18:1606-1612. [PubMed]
12. IL32 splice variant Reference Sequence retrieved from NCBI. [website]
13. IL32 specific protein and corresponding transcript sequences used to generated antibody used in study. [Website]
14. Netea MG, Azam T, Lewis EC, et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma dependent mechanism. PLoS Med 2006; 3:1310-1319. [PubMed]
15. Netea MG, Azam T, Ferwerda G, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 2005; 102: 16309–16314. [PubMed]
16. Stuyt RJ, Netea MG, Kim SH, et al. Differential roles of interleukin-18 (IL-18) and IL-12 for induction of gamma interferon by staphylococcal cell wall components and superantigens. Infect Immun 2001; 69: 5025–5030. [PubMed]
17. Calabrese F, Baraldo S, Bazzan E, et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178:894-901. [PubMed]
18. Shioya M, Nishida A, Yagi Y, et al. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease.Clin Exp Immunol 2007; 49:480-486. [PubMed]
19. Oh JH, Cho MC, Kim JH, et al. IL32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene 2011; 30:3345-3359. [PubMed]
20. Goda C, Kanaji T, Kanaji S, et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 2006;18: 233–240. [PubMed]
21. Zheng LM, Ojcius DM, Garaud F, et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996;184: 579–584. [PubMed]
22. Sorrentino C, Di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 2009; 180: 769–779. [PubMed]
READ THE FULL ARTICLE
1. Access this article through OpenAthens
3. Purchase this article at rate $55.00 and received Full-Text/PDF
You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use. Use the coding below to purchase your article as PDF by credit card, debit card, will be asked to supply your billing card information. Before continue with your purchase please read carefully the BM-Publisher terms and conditions of purchase.
For any technique error please contact us and will be response to sending purchase article by email.
Who Can Become a Reviewer?
Any expert in the article's research field can become a reviewer with American Journal of Biomedicine. Editors might ask you to look at a specific aspect of an article,...
Thank you for visiting American Journal of BioMedicine. * = Required fields
American Journal of BioMedicine Volume 1, Issue 2, pages 73-85
Received July 22, 2013; accepted November 03, 2013; published December 11, 2013
How to cite this article
Neuzillet JM, Traynor C, Hullmann G, Tyritzis G, Shimizu J. TNF-α-induced IL-32 expression in esophageal cancer: cross talk JNK/Akt signaling pathways. American Journal of BioMedicine 2013;1(2):73-85.
4. Materials and Methods